NCT02477475 is a clinical trial in Reflux Esophagitis, sponsored by AstraZeneca.

Who is sponsoring NCT02477475?

NCT02477475 is sponsored by AstraZeneca.

What condition does NCT02477475 study?

NCT02477475 studies Reflux Esophagitis.

Is NCT02477475 still recruiting?

NCT02477475 is currently completed. Last updated 21 June 2017.

Last reviewed 2017-06-21 · How we verify

NCT02477475

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Completed Last updated 21 June 2017

What this trial tests

trial in Reflux Esophagitis in 1,595 participants. Completed in 20 February 2017.

Timeline

7 July 2015

Primary endpoint
20 February 2017

20 February 2017

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,595
Start date	7 July 2015
Primary completion	20 February 2017
Estimated completion	20 February 2017
Sites	47 locations across Japan

Conditions studied

Reflux Esophagitis — all drugs for Reflux Esophagitis →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Reflux Esophagitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Reflux Esophagitis

Currently open trials in the same condition.

NCT06475170 — Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02477475 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 21 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02477475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing